Stopping Your GLP-1 Could Raise Your Heart Attack Risk by 22%

What Happens When You Stop Taking a GLP-1?

A 2026 analysis from Washington University School of Medicine examined outcomes in veterans with type 2 diabetes who discontinued GLP-1 receptor agonist therapy. The findings were striking: even brief interruptions in treatment — as short as six months — were associated with higher risk of heart attack, stroke, and death compared with continuous use.

The risks escalated with time off therapy. After two years without GLP-1 medication, patients faced up to a 22% increase in the risk of a major adverse cardiovascular event (MACE). This was not simply weight regain — researchers observed rapid reversal of multiple protective mechanisms.

It Is Not Just About the Weight Coming Back

Weight regain after stopping GLP-1 therapy is well-documented. A BMJ study published in January 2026 confirmed that people who stop weight-loss medications regain the weight within an average of 1.7 years, accompanied by worsening of cardiometabolic risk factors including A1C and blood pressure.

But the cardiovascular risk reversal appears to happen faster than the weight regain. Researchers observed that patients who stopped GLP-1s saw:

• Inflammation markers (CRP) rise back toward pre-treatment levels
• Insulin resistance return
• Blood pressure increase
• Cholesterol levels climb

As the lead researcher noted: building cardiovascular protection takes a long time, but undoing it takes about half as long. A year of GLP-1 therapy's heart protection can be erased in approximately six months.

Why Does This Happen?

GLP-1 receptor agonists provide cardiovascular protection through several mechanisms beyond weight loss: they reduce systemic inflammation, improve endothelial function, lower blood pressure, and improve lipid profiles. The SELECT trial demonstrated that semaglutide reduced MACE by 20% in patients with obesity and cardiovascular disease — independent of diabetes status.

When the drug is removed, these protective effects do not persist. The body's metabolic environment reverts toward its pre-treatment state, and without the drug's anti-inflammatory and cardioprotective properties, the accumulated benefit dissipates.

Scenarios Where Stopping Comes Up

In clinical practice, patients discontinue GLP-1 therapy for several common reasons. Each one deserves a specific conversation with your prescriber:

• Cost. Insurance changes, job loss, or coverage gaps are the most common reason for discontinuation. If cost is the issue, ask your doctor about switching to a lower-cost compounded option or the new oral formulations, which start at $149/month for cash-pay patients.
• Side effects. Persistent nausea or GI distress leads some patients to stop. Before quitting entirely, discuss dose reduction, switching medications, or trying the oral formulation, which some patients tolerate differently.
• Goal weight reached. Some patients assume they can stop once they hit their target weight. This research suggests that abrupt discontinuation is risky, especially for patients with cardiovascular risk factors. A gradual taper with close monitoring may be preferable.
• Pregnancy planning. GLP-1 medications are contraindicated in pregnancy. Women should stop at least two months before attempting to conceive (five weeks for tirzepatide). Have this conversation with your OB-GYN and prescriber together.
• Supply disruption. While less common in 2026 than in previous years, shipping delays or pharmacy switches can create involuntary gaps. If you anticipate an interruption, ask your prescriber about bridging strategies.

How to Talk to Your Doctor About This

If you are considering stopping your GLP-1 medication, bring these specific questions to your appointment:

• What is my current cardiovascular risk profile? (Request recent labs including CRP, lipid panel, A1C.)
• What is the safest way to discontinue — gradual taper versus abrupt stop?
• What monitoring should we do after stopping — and how frequently?
• Are there lower-cost alternatives that would let me continue some form of GLP-1 therapy?
• If I stop and my numbers worsen, how quickly can I restart?